Literature DB >> 3919149

Respiratory syncytial virus polypeptides. IV. The oligosaccharides of the glycoproteins.

C Gruber, S Levine.   

Abstract

The cell-associated glycoproteins of respiratory syncytial (RS) virus included GP1 (90K), VP70 (70K), VGP48 (48K) and GP26 (26K). Although present in infected cells, there was no VP70 in purified virus. Trypsin treatment of infected cells removed 80 to 90% of VP70 as well as its products VGP48 and GP26. This suggested that most of the VP70 in the cell is located on the plasma membrane. The glycoproteins of purified RS virus (GP1, VGP48 and GP26) contain mannose, galactose and fucose as well as glucosamine, but the quantity of mannose in GP1 is low when compared to that of the other three sugars. The effects that follow the treatment of infected cells with the glycosylation inhibitors tunicamycin and monensin, and the treatment of the immunoprecipitated product of pulse-chase experiments with endonuclease H demonstrated that VP70 and its products contained N-linked oligosaccharides, and that the oligosaccharides of the mature VGP48 subunit were of the complex type, while GP1 contained both N- and O-linked oligosaccharides. The non-glycosylated forms of VP70 and GP1 have estimated mol. wt. of 50K and 33K respectively. Therefore, the carbohydrate contribution to the mol. wt. of VP70 and GP1, as determined by PAGE, was equivalent to 20K for the former and 57K for the latter. The majority of the GP1 oligosaccharides were O-linked, a form of sugar linkage not previously found among paramyxoviruses.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3919149     DOI: 10.1099/0022-1317-66-3-417

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  29 in total

1.  Glycosylation and oligomerization of the spike protein of Marburg virus.

Authors:  H Feldmann; C Will; M Schikore; W Slenczka; H D Klenk
Journal:  Virology       Date:  1991-05       Impact factor: 3.616

2.  O-linked glycosylation of retroviral envelope gene products.

Authors:  A Pinter; W J Honnen
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

3.  O glycosylation of glycoprotein G of human respiratory syncytial virus is specified within the divergent ectodomain.

Authors:  P L Collins
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

4.  Processing, surface expression, and immunogenicity of carboxy-terminally truncated mutants of G protein of human respiratory syncytial virus.

Authors:  R A Olmsted; B R Murphy; L A Lawrence; N Elango; B Moss; P L Collins
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

5.  Interprotein disulfide bonding between F and G glycoproteins of human respiratory syncytial virus.

Authors:  R G Arumugham; S W Hildreth; P R Paradiso
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

6.  Further characterization of the soluble form of the G glycoprotein of respiratory syncytial virus.

Authors:  D A Hendricks; K McIntosh; J L Patterson
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

7.  N-glycans of F protein differentially affect fusion activity of human respiratory syncytial virus.

Authors:  G Zimmer; I Trotz; G Herrler
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

8.  Respiratory syncytial virus envelope glycoprotein (G) has a novel structure.

Authors:  M Satake; J E Coligan; N Elango; E Norrby; S Venkatesan
Journal:  Nucleic Acids Res       Date:  1985-11-11       Impact factor: 16.971

9.  The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein G are synthesized from alternative initiation codons.

Authors:  S R Roberts; D Lichtenstein; L A Ball; G W Wertz
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

10.  Site-directed serology with synthetic peptides representing the large glycoprotein G of respiratory syncytial virus.

Authors:  E Norrby; M A Mufson; H Alexander; R A Houghten; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.